Multicenter, randomized, open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC, including histologic subtypes of papillary, unclassified, and translocation-associated.
Principal Investigator: Katriina Peltola
HUS Helsinki University Hospital, Comprehensive Cancer Center
Link to the ClinicalTrials.gov study website
